Gan & Lee(SH:603087) Zhong Guo Xin Wen Wang·2025-05-16 03:46Core Insights - The biopharmaceutical industry continues to focus on international expansion, with Chinese pharmaceutical companies completing 40 overseas licensing deals worth $38 billion in the first quarter of 2025 [1] - The partnership between Gan Li Pharmaceutical and Brazil's Biomm marks a significant step in local insulin production, addressing the high demand for insulin in Brazil due to rising diabetes rates [2] Group 1: Industry Trends - The global diabetes epidemic is driving demand for insulin, particularly in Brazil, where local production is essential to mitigate supply chain risks [1][2] - The PDP project aims to enhance Brazil's public health system by ensuring the availability of insulin, thereby strengthening the local biopharmaceutical industry [2] Group 2: Company Developments - Gan Li Pharmaceutical has established a long-term partnership with Biomm since 2014, enabling the latter to become Brazil's first local producer of insulin through technology transfer [1][2] - The company's international revenue has significantly increased from 93 million yuan to 528 million yuan between 2020 and 2024, with the international revenue share rising from 2.76% to 17.33% [2]